Compare TRMK & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | TRVI |
|---|---|---|
| Founded | 1889 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | TRMK | TRVI |
|---|---|---|
| Price | $46.13 | $17.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $44.50 | $21.55 |
| AVG Volume (30 Days) | 468.7K | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | 1.93 | ★ 31.91 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $4.86 | N/A |
| P/E Ratio | $48.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.11 | $6.55 |
| 52 Week High | $47.44 | $20.15 |
| Indicator | TRMK | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 55.91 |
| Support Level | $43.28 | $10.07 |
| Resistance Level | $46.34 | $20.15 |
| Average True Range (ATR) | 0.83 | 1.08 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 52.85 | 40.41 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.